ReviewRadiologie (Heidelberg, Germany)2025
[Radiotherapy of non-Hodgkin lymphoma-discussion of modern treatment concepts and innovations].
Review in Radiologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy is an established treatment modality for malignant non-Hodgkin lymphoma. However, the complexity of the treatment situations demands precise treatment indication and execution. The following review presents modern radiooncological treatment strategies. MATERIALS AND
methodsA selective literature search addressing radiotherapy of malignant non-Hodgkin lymphoma was conducted, focusing on diffuse large B‑cell lymphoma, marginal zone lymphoma, and follicular lymphoma. Relevant studies as well as the German national S3 guidelines were identified and discussed.
resultsIndolent lymphoma in early stages can be treated with radiotherapy in curative intent. In carefully selected cases, dose de-escalation may be possible, although it is not recommended by the German S3 guideline. In the case of aggressive non-Hodgkin lymphoma, consolidation radiotherapy is conducted after systemic therapy, addressing regions with an increased risk of recurrence. Particularly patients with positron-emission tomography (PET)-positive residuals should be irradiated. Innovations like the application of radiotherapy before or after chimeric antigen receptor T‑cell therapy and the emerging implementation of online adaptive radiotherapy will enrich the therapeutic landscape in the future.
Indexed as
Identifiers
40500431What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.